



18 May 2021

Creso Pharma finalises development of the new hemp flour-based anibidiol® swine to enter the global livestock market

Highlights:

- **Development of anibidiol® swine product finalised – a hemp flour and oat bran complimentary feedstock for swine**
- **Product developed to lower stress and discomfort in pig herds and reduce tail biting which can impact the commercial value of animals at slaughter**
- **First sales expected in Europe and Latin America during H2 CY2021**
- **Launch will mark Creso Pharma's entry into the lucrative livestock market**
- **Swine hemp-based complementary feed market is a very attractive opportunity – there are ~700m pigs globally with a population of 150m pigsⁱ in Europe**
- **anibidiol® swine will be marketed by Creso's established animal health partners**
- **New product represents product portfolio expansion and the strengthening of Creso Pharma's animal health footprint globally**

Creso Pharma Limited (ASX:CPH, FRA:1X8) ('Creso Pharma' or 'the Company') is pleased to advise that it has finalised the development of anibidiol® swine, a new and innovative hemp flour and oat bran based complementary feed product to support stress reduction and wellbeing with pigs reared indoors and outdoors. The new product marks another step in the Company's strategic portfolio expansion and provides Creso Pharma with an entry point into the livestock market.

anibidiol® swine was developed to address tail biting in pig herds. Tail biting is a common problem and can result in lesions that may decrease the value of the animal at slaughterⁱⁱ. Tail biting varies in severity from light manipulation to a physical harming the tail, causing infection, amputation or even harming areas surrounding the tail.

A common cause of tail biting is pigs feeling stress or discomfort, with the action diverting the animal's attentionⁱⁱⁱ. Stressful situations, boredom and frustration enhance tail biting. Previous reports have shown a positive impact when using hemp plants to reduce pig stress and pig tail biting.

Creso Pharma began developing anibidiol® swine in March 2020, following concerns expressed by farmers. anibidiol® swine is Swiss made and produced of Swiss GAP compliant industrial, in line with the European Feed Catalogue.

The product is expected to bring considerable benefits to pig herds and support stress reduction and contribute to a reduction in the occurrence of tail biting. The product provides farmers with an attractive hemp based animal health focused complementary feedstock which may address some of the needs expressed by pig farmers. anibidiol® swine represents an important strategic portfolio expansion providing Creso Pharma with entry into another lucrative area beyond its existing reach in the household pet market.



anibidiol® swine 250g 3% CBD hemp flour

Creso Pharma will begin marketing the product to farmers and breeders through its established partners and distributors in the animal health space. The Company's initial focus will be on Europe and Latin American markets. First sales are expected with vets, livestock feed shops and online during H2 CY2021.

The livestock and swine feed market provides a very lucrative opportunity for Creso Pharma. The swine feed market projected to grow to US\$148.17Bn by 2027 with a population of over 150m pigs in Europe and 67 million pigs in Latin America^{iv}.

Commentary

Creso Commercial and Development Director, Dr. Gian Trepp, said: *"anibidiol® swine was developed to address the large need expressed by farmers for an effective, natural and plant based complementary feed to support the reduction of stress and swine tail biting.*

"The development follows considerable work undertaken by the Creso Pharma team and we are very pleased to have this product ready for launch on a global basis. We anticipate that the launch will provide access into another lucrative vertical for the Company and contribute to the Company's growing revenue streams."

Ends-

Authority and Contact Details

This announcement has been authorised for release by the Board of Creso Pharma Limited.

For further information, please contact:

Investor Enquiries

EverBlu Capital

E: info@everblucapital.com

P: +61 2 8249 0000



Released through:

Ben Jarvis, Six Degrees Investor Relations: Ph: +61 (0) 413 150 448

About Creso Pharma

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health.

Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit: www.cresopharma.com

Forward Looking statements

This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent required by applicable laws.

ⁱ European Parliamentary Research Service (EPRS) 2020

ⁱⁱ Schrøder-Petersen, D.L; Simonsen, H.B (November 2001). "Tail biting in pigs". *Veterinary Journal*. 162 (3): 196–210. doi:10.1053/tvjl.2001.0605. PMID 11681870.

ⁱⁱⁱ van den Berg, J (1 October 1982). "[Tail-biting in pigs. Causes, effects and prevention]". *Tijdschrift voor diergeneeskunde (in Dutch)*. 107 (19): 735–43. PMID 7147219

^{iv} Mordor Intelligence Report 2019